Meeting
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
Presenter
E. Antonio Chiocca, MD, PhD
Brigham and Women's Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03636477
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2510)
DOI
10.1200/JCO.2020.38.15_suppl.2510
Abstract #
2510
Poster Bd #
1
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study.
Speaker: Stephen Joseph Bagley, MD, MSCE
Videos & Slides
2018 ASCO Annual Meeting
Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma.
Speaker: John Frederick De Groot, MD
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101, an inhibitor of the transcription factor C/EBPβ.
Speaker: Fabio Massaiti Iwamoto, MD
Videos & Slides
2024 ASCO Annual Meeting
Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).
Speaker: Gilbert Youssef, MD